Yellow fever (YF) remains an important public health problem and the 17D live, attenuated yellow fever virus vaccine constitutes the single most effective means of limiting impact of the disease [1] [2] [3] . The World Health Organization (WHO) recommends that persons aged .9 months who are traveling to or living in areas where yellow fever infection is officially reported should be vaccinated [4] [5] [6] [7] [8] . In Brazil, the YF-17DD vaccine is offered for free to every citizen by the National Immunization Program and was introduced into the routine vaccination schedule in endemic and risk areas in 2005, and is currently administered at 9 months of age [9] .
The YF vaccine immunogenicity in adults reaches over 95% of vaccinees that may persist for at least 35 years [10] . However, the rates of seroconversion in children ranged from 77.5% to 90%, with distinct seroconversion rates observed according to the age at vaccination [11] [12] [13] [14] [15] [16] [17] .
The immaturity of the immune system [18] [19] [20] [21] [22] and the presence of passively acquired maternal antibody in the serum of the young infant may have an immunosuppressive effect on the development of the infant's own immune response [23] [24] [25] , and has been presented to account for the decreased humoral immune response of the younger infants.
Despite the extensive literature covering the humoral immune response triggered by the YF vaccines in adults and children, knowledge about the overall cellular immunity following YF immunization still remains to be elucidated, with few studies focusing the multiparametric aspects of the innate and adaptive immunity following YF vaccination [26] [27] [28] [29] [30] [31] [32] [33] . Studies performed in primovaccinated adults have demonstrated the coexistence of activation events and modulatory pathways. In addition, a mixed pattern of cytokine profile is also observed as the hallmark of YF-17DD vaccination in adults [31] [32] [33] . Regardless of the relevance of the immune response triggered parallel to the establishment of distinct patterns of seroconversion after YF vaccination, there are no studies covering the issue of overall cellular immunity.
The purpose of this study is to evaluate whether the immune response triggered in YF-17DD-vaccinated children resembled the overall pattern previously described in adults and whether the cellular immune response is somehow related to the levels of YF-neutralizing antibodies. To test these hypotheses, we have characterized the impact of YF antigen recall in the intracytoplasmic cytokine pattern of peripheral blood leukocytes and the association between specific cytokine signatures with distinct postvaccination seroconversion status.
METHODS

Study Population
This study was coordinated by the Collaborative Group for Studies of Yellow Fever Vaccine [34] and included 60 healthy children (34 males and 26 females) from 9 to 43 months of age, living in the metropolitan area of Belo Horizonte-Minas Gerais and Brasília-Distrito Federal, Brazil.
The study was approved by the Ethical Committee of Oswaldo Cruz Foundation FIOCRUZ-protocol number 236A/03. The children were formally included in the study if the free and informed consent form was signed by parents or legal guardians.
Prior to and 30 days after YF-17DD vaccination, children were requested to provide a blood sample to detect anti-YFneutralizing antibodies using the plaque reduction neutralization test (PRNT), performed as described by Stefano et al. [12] . The tests were carried out at Laborató rio de Tecnologia Viroló gica, Bio-Manguinhos/FIOCRUZ, under the supervision of one of us (M. S. F.). The results are expressed as milliInternational Units/mL (mIU/mL). A PRNT result of $2.5 log 10 mIU/mL was used as the cut-off mark to segregate seroconverters from negative and nonseroconverters.
According to the PRNT results at 30 days post vaccination, the children were classified as seroconverters (PRNT $ 2.5 log 10 mIU/mL) or nonseroconverters (PRNT , 2.5 log 10 mIU/mL), and referred as PV-PRNT 1 (n 5 30, 15 males and 15 females, age range 9-12 months, median 5 9 months) and PV-PRNT 2 (n 5 10, 6 males and 4 females, age range 12-14 months, median 5 12 months), respectively. Children within the PRNT 1 group were subdivided into 2 groups named PV-PRNT MEDIUM1 (2.5 # PRNT # 3.5 log 10 mIU/mL, n 5 20)
and PV-PRNT HIGH1 (PRNT . 3.5 log 10 mIU/mL, n 5 10).
The PV-PRNT 2 volunteers were submitted to revaccination 1 year after primovaccination and referred to as RV-PRNT 1 (n 5 9, 6 males and 4 females, age range 40-43 months, median 5 41 months) because all volunteers seroconvert after revaccination (PRNT $ 2.5 log 10 mIU/mL). One year after primo/revaccination, peripheral blood samples (7 mL) were collected into Vacutainer tubes containing sodium heparin (Becton Dickinson, San Jose, CA) for short-term whole blood cultures and intracytoplasmic cytokines analyses by flow cytometry.
Blood samples from 10 unvaccinated seronegative children (PRNT , 2.5 log 10 mIU/mL, 7 males and 3 females, age range 9-12 months, median 5 9 months) collected prior to vaccination were included as a control group and referred to as UV-PRNT.
Short-term Whole Blood Culture and Intracytoplasmic Cytokine Staining
In vitro short-term cultures of whole blood samples were performed as described by Luiza-Silva et al. [33] and modified as follows: aliquots of heparinized peripheral blood were incubated for 6 hours at 37°C, 5% CO 2 , in the presence of RPMI 1640 medium (GIBCO, Grand Island, NY; control culture) or in the presence of live attenuated YF-17DD vaccine (lot 055VFA054P, Bio-Manguinhos, FIOCRUZ) at a final concentration of 2. 
Flow Cytometry Acquisition and Analysis
Immunostained samples were acquired using a FACScalibur flow cytometer, and CELLQuest software was used to perform data acquisition and analysis. A total of 30,000 events/tube were acquired and stored for further analysis. Distinct gating strategies were used to analyze the cytokine-expressing leukocytes subsets, including neutrophils, monocytes, natural killer (NK) cells, and lymphocytes (CD4 1 , CD8 1 T-cell subsets, and B cells) as previously reported by Luiza-Silva et al. [33] . The results were first expressed as percentages of cytokine-positive cells for different gated leukocyte subpopulations analyzed in this study. These values were used to obtain the cytokine index, calculated as the ratio between the percentage of cytokine-positive cells observed in the stimulated culture (YF-Ag) by the percentage of cytokinepositive cells observed in the unstimulated culture (control).
Cytokine Signature Analysis
The cytokine profile was first assessed to identify low and high cytokine producers, as previously suggested by Luiza-Silva et al. [33] . Briefly, after the establishment of the global median YF-Ag/control index, each leukocyte subsets from all volunteers were tagged as they display low ( ), high proinflammatory ( ), or high regulatory ( ) cytokine indexes. The percentage of volunteers showing high cytokine indexes was calculated for each leukocyte subset. The ascendant frequency of high cytokine indexes for PV-PRNT 1 was then used as the reference cytokine curves ( ) to identify changes in the overall cytokine patterns from all other groups. Radar charts were further used to summarize the proinflammatory ( ) or regulatory ( ) cytokine signatures in a range of leukocyte subsets of innate and adaptive immunity. Each axis represents the frequency (%) of volunteers showing high cytokine indexes.
Statistical Analysis
Statistical analyses between groups were performed by parametric analysis of variation (ANOVA) followed by Student t test or nonparametric Kruskal-Wallis test followed by the MannWhitney test. Spearman rank correlation test was performed to assess the association between the levels of PRNT antibodies (log 10 mIU/mL) and the cytokine indexes (YF-Ag/control). In all cases, significance was considered at P # .05. All tests were provided by GraphPad Prism version 5.0 (San Diego, CA).
The analysis of cytokine signatures was performed using the PV-PRNT 1 cytokine signature as the reference curve, and significant differences were considered when the values emerged outside the quartile of the reference signature. Aiming to further characterize the overall cytokine signature of innate and adaptive immunity compartments, we have calculated Figure 1 . Impact of YF-Ag in the cytokine profile of innate immune cells from UV-PRNT 2 (in white), PV-PRNT 2 (in light gray), PV-PRNT 1 (in black), and RV-PRNT 1 (in dark gray) children groups 1 year after YF-17DD vaccination or revaccination. Intracytoplasmic cytokine studies were performed after in vitro short-term incubation. To identify neutrophils (top panels) and NK cells (bottom panels), anti-CD16 TC mAbs were used, and to identify monocytes (middle panels) CD14 TC mAbs were used. Anti-cytokines-PE mAbs were used to determine inflammatory and regulatory cytokines ) that were applied to identify changes in the overall cytokine signature from all other groups. the innate and adaptive immunity, despite the overall impairment of NK cells (Figure 3 ).
RESULTS
Impact of In
Overall Pattern of Proinflammatory and Regulatory High Cytokine Producers Triggered by YF-Ag Recall in 17DD Vaccinees
In order to further characterize the overall cytokine pattern of YF-17DD-vaccinated children, we have constructed radar charts to characterize the frequency of high proinflammatory and regulatory cytokine producers in the PV-PRNT 1 group (Figure 4 , top chart) to be used as a standard to identify changes in the overall cytokine pattern in PV-PRNT
2
, RV-PRNT
1
, and UV-PRNT 2 ( Figure 4 , middle and bottom charts).
Our data demonstrate that the overall cytokine pattern of the PV-PRNT Based on the serum levels of anti-YF-neutralizing antibodies, the 17DD primovaccinees were categorized into 3 distinct subgroups, referred to as PRNT 2 , PRNT MEDIUM1 , and PRNT
HIGH1
. Using this criterion, our data demonstrated that all UV-PRNT 2 and PV-PRNT 2 were confined to a level below the cut-off mark (,2.5 log 10 mUI/mL). The PV-PRNT 1 and RV-PRNT 1 groups presented levels of neutralizing antibodies above the cut-off mark ($2.5 log 10 mUI/mL). The PV-PRNT 1 group presented distinct patterns of neutralizing antibodies, including MEDIUM (2.5-3.5 log 10 mUI/mL) or HIGH (.3.5 log 10 mUI/mL) ( Figure 5 Taken together, our results demonstrated in YF-17DD primovaccinees that the overall signature of high cytokine producers triggered by YF-Ag recall is associated with the levels of anti-YF-neutralizing antibodies, with a balanced proinflammatory and regulatory profile of innate and adaptive immunity being the hallmark of PV-PRNT MEDIUM1 , whereas a polarized regulatory signature is observed in PV-PRNT 2 and a prominent proinflammatory signature is characteristic of PV-PRNT
.
DISCUSSION
The purpose of our study is to evaluate immune responses in infants vaccinated at 9 months of age with YF-17DD vaccine through detailed investigation of the in vitro YF antigens impact in the intracytoplasmic cytokine pattern of peripheral innate and adaptive leukocytes, aiming to characterize the cytokines profile involved with status vaccination.
Little is known about the immune response in children following YF vaccination. Previous reports have postulated that infants have deficiencies in primary antigen presentation by dendritic cells, limited T-cell proliferation, impaired B-cell function, and reduced production of cytokines by helper T cells of the type 1 subset (TH1), including interleukin 2 (IL-2) and interferon gamma (IFN-c) [35] [36] [37] [38] [39] [40] [41] . In the present investigation, our data demonstrated that the impact of in vitro YF-vaccinal antigen stimuli on the cytokine profile of innate and adaptive immunity in YF-17DD primovaccinated children promoted distinct immunological profiles characterized by a balanced involvement of proinflammatory/regulatory adaptive immunity with a prominent participation of the innate immunity proinflammatory events in the PV-PRNT 1 group mediated by IL-12 in the innate immunity compartment besides an overall increased adaptive regulatory profile. This resultant regulatory profile observed in PV-PRNT 2 children, similar to that observed in unvaccinated children (UV-PRNT 2 ), suggests a putative vulnerability of these subjects to develop a risky immune response upon contact with the wild-type YF virus, favoring viral replication, especially due to the lack of proinflammatory pathways in the innate immunity.
Interestingly, when the PV-PRNT 2 children were revaccinated, all volunteers seroconverted and the overall regulatory cytokine signature were shifted toward a proinflammatory status, similar to that observed in the seroconverter group (PV-PRNT T cells. These data demonstrated that along with the seroconversion event, the 17DD-YF vaccine booster was able to restore almost all immunological events observed in the ideal reference cytokine signature characterized by a balanced involvement of proinflammatory/regulatory immunity. The presence of neutralizing antibodies along with the pro-inflammatory/regulatory cytokine signature observe in the re-vaccinated children may represent a relevant biomarker of protective immunity upon the contact with the YF wild virus. This shift in the immunological status suggests that revaccination could be helpful to guarantee the seroconversion besides a protective cellular immune response, especially in endemic areas where vaccination is the primary way to prevent infection and children are constantly exposed to wild YF virus. Our data demonstrated that the overall cytokine signature observed in the PV-PRNT 1 group was somehow associated with the levels of PRNT antibodies, with a predominant proinflammatory pattern observed in those individuals that displayed a higher PRNT profile. These finding may suggest that higher levels of PRNT antibodies may be a good biomarker, and may be associated with a prominent antiviral immune response.
It is important to note that this study focused mainly on the interface of the humoral and cellular immune response with regard to major consequences that distinct patterns of seroconversion may have in the overall cytokine signaturesbiomarkers of the cellular immune response. However, our investigation did not accomplish an important issue regarding the YF-17DD vaccination in children-the mechanisms underlying the establishment of distinct status of seroconversion observed in YF vaccinees [11] [12] [13] [14] [15] [16] [17] . Several proposals have been presented to explain this phenomenon, including the vaccine substrain (17D-204, 17D-213/77, or 17DD), the presence of residual maternal antibodies, the baseline cytokine signature at the individual level, and the interference of simultaneous viral vaccination [18] [19] [20] [21] [22] [23] [24] [25] . The Collaborative Group for the Study of Yellow Fever Vaccines has already reported in an observational multicenter study [17] that the age at primovaccination is a relevant variable that would contribute to the seroconversion rate.
In that investigation, the 17DD-YF vaccine reached higher seroconversion rates among children older than 2 years: 97% among children .10 years and 94% among children 2-9 years old; data showed lower seroconversion rates in children ,2 years: 88% for 12-23-month-olds, 72% for 9-11-month-olds, and 82% for 6-8-month-olds. In the present study, the age was not related to the lack of seroconversion after YF-17DD, since the mean age in the PV-PRNT 2 was even higher in comparison with the PV-PRNT
1
. Complementary kinetic studies early after YF-vaccination are still required to elucidate the mechanism responsible for the distinct profile of seroconversion.
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